Claims

Predictive validity, cost, and differential attainment by demographics are not indicated in the prescribing assessment literature

Claim · All claims
Evidence · 1 study · review r3 · q3
Currency · newest study 2025 · checked against its sources 2026-10-31 (automated, 1 of 1 entry) · not reviewed by a person

Subclaims

Reading the evidence codes

q is the design tier, i the impact, n the sample, and the kind with its r the rigour judged within that kind: what each code means.

This claim: no standardized effect is recorded in observations/ for it yet, so no benchmark reading is possible.

q3 i? The reviewed studies did not report costs of developing and delivering assessments, differential attainment by demographics, or predictive validity. → McLachlan JC 2025

Evidence

McLachlan JC 2025

McLachlan JC, Auta A, Ajiboye A. (2025). Assessment and evaluation of prescribing competences: A systematic review and recommendations. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16033

q3 · i? · review · r3

The review's synthesis of reporting practices across included studies found that "Costs of developing and delivering assessments, differential attainment by demographics, and predictive validity were not indicated."

"Costs of developing and delivering assessments, differential attainment by demographics, and predictive validity were not indicated."

Discussion

Page metadata
Field Value
status review
generated by process:wiki-ingest on 2026-10-31
trust unverified — no one has confirmed this page's content

Frontmatter is the page's machine-readable record — see the Schema & Guide.